Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPEP | Q07075 | 16/20 | 0.45 |
| ▸ | GNPAT | O15228 | 1/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30271497 | 0.93 | ENPEP (0.44) | ENPEPGNPATCTSDBACE1 | |
| SCHEMBL31181173 | 0.89 | ENPEP (0.44) | ENPEPGNPATCTSDBACE1 | |
| SCHEMBL29698219 | 0.89 | ENPEP (0.44) | ENPEPGNPAT | |
| SCHEMBL29355062 | 0.89 | ECE1 (0.50) | ENPEPCTSDBACE1MME | |
| SCHEMBL29452545 | 0.89 | PDCD1LG2 (0.47) | ENPEPGNPATMME | |
| SCHEMBL29832701 | 0.88 | NOD1 (0.44) | ENPEPCTSDBACE1 | |
| SCHEMBL30798028 | 0.86 | GNPAT (0.53) | ENPEPGNPATMME | |
| SCHEMBL30798044 | 0.86 | GNPAT (0.53) | ENPEPGNPATMME | |
| SCHEMBL31181245 | 0.86 | ENPEP (0.57) | ENPEP | |
| SCHEMBL30053992 | 0.86 | PDCD1LG2 (0.48) | ENPEPGNPATCTSDBACE1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360179-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-10-31 | — | — | US | disclosed |
| CN-118675607-A | BNCT boron drug targeting thrombofibrin and screening method thereof | 北京华牛世纪生物技术研究院 | 2024-09-20 | — | — | CN | disclosed |
| CN-117129590-A | Application of endogenous metabolite in preparation of aplastic anemia diagnosis product | 苏州派博思生物技术有限公司 | 2023-11-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360179-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | ENPEP 35/4885GNPAT 3500/4885CTSD 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.